SCHEMBL24253955

SCHEMBL24253955

CCOC(=O)c1nc(N2CCC3(CCCC(=O)N3c3ccc(F)c(F)c3)CC2)cc(C(F)(F)F)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
NR1H2 P55055 2/20 0.35
NR1H3 Q13133 1/20 0.35
NPSR1 Q6W5P4 3/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
HTT P42858 1/20 0.33
P2RY12 Q9H244 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
FFAR4 Q5NUL3 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494606 1.00 HPGD (0.35) HPGDALDH1A1MAPTMEN1KMT2A
SCHEMBL24253953 0.88 FFAR4 (0.34) NPSR1FFAR4TSHRHCRTR1HCRTR2
SCHEMBL30424528 0.88 FFAR4 (0.34) NPSR1FFAR4TSHRHCRTR1HCRTR2
SCHEMBL30423952 0.82 HCRTR1 (0.34) FFAR4HCRTR1HCRTR2SLC6A2SLC6A3
SCHEMBL24253948 0.82 HCRTR1 (0.34) FFAR4HCRTR1HCRTR2SLC6A2SLC6A3
SCHEMBL24253742 0.82 DRD3 (0.39) DRD2DRD3
SCHEMBL30423984 0.82 DRD3 (0.39) DRD2DRD3
SCHEMBL30494596 0.82 POLB (0.33) HPGDALDH1A1POLBNPSR1ALOX15
SCHEMBL24253911 0.82 POLB (0.33) HPGDALDH1A1POLBNPSR1ALOX15
SCHEMBL24253952 0.81 MAPT (0.34) MAPTNPSR1SMN1; SMN2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 HPGD 1176/4885ALDH1A1 323/4885MAPT 4450/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 HPGD 1176/4885ALDH1A1 323/4885MAPT 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.